|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
Statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vogelstein B, Fearon ER, Hamilton SR, Kern
SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos
JL: Genetic alterations during colorectal-tumor development. N Engl
J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mäkinen MJ, George SM, Jernvall P, Mäkelä
J, Vihko P and Karttunen TJ: Colorectal carcinoma associated with
serrated adenoma-prevalence, histological features, and prognosis.
J Pathol. 193:286–294. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
O'Brien MJ, Yang S, Huang CS, Shepherd C,
Cerda S and Farraye FA: The serrated polyp pathway to colorectal
carcinoma. Diagn Histopathol. 14:78–93. 2008. View Article : Google Scholar
|
|
5
|
Snover DC, Ahnen DJ and Burt RW: Serrated
polyps of the colon and rectum and serrated polyposisBosman FT,
Carneiro F, Hruban RH and Theise ND: WHO classification of tumours
of the digestive system. IARC P; Lyon, France: pp. 160–165.
2010
|
|
6
|
Huang CS, Farraye FA, Yang S and O'Brien
MJ: The clinical significance of serrated polyps. Am J
Gastroenterol. 106:229–240. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bettington M, Walker N, Clouston A, Brown
I, Leggett B and Whitehall V: The serrated pathway to colorectal
carcinoma: Current concepts and challenges. Histopathology.
62:367–386. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cunningham JM, Christensen ER, Tester DJ,
Kim CY, Roche PC, Burgart LJ and Thibodeau SN: Hypermethylation of
the hMLH1 promoter in colon cancer with microsatellite instability.
Cancer Res. 58:3455–3460. 1998.PubMed/NCBI
|
|
9
|
Ohta M, Inoue H, Cotticelli MG, Kastury K,
Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, et al:
The FHIT gene, spanning the chromosome 3p14.2 fragile site and
renal carcinomaassociated t(3;8) breakpoint, is abnormal in
digestive tract cancers. Cell. 84:587–597. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huebner K and Croce CM: Cancer and the
FRA3B/FHIT fragile locus: It's a HIT. Br J Cancer. 88:1501–1506.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kuwai T, Tanaka S, Kaio E, Hiyama T, Ito
M, Kitadai Y, Sumii M, Yoshihara M, Haruma K and Chayama K:
Clinical significance of Fhit expression in development of
colorectal carcinoma of various macroscopic types. Int J Mol Med.
12:437–442. 2003.PubMed/NCBI
|
|
12
|
Mimori K, Ishii H, Nagahara H, Sudo T,
Yamashita K, Inoue H, Barnard GF and Mori M: FHIT is up-regulated
by inflammatory stimuli and inhibits prostaglandin E2-mediated
cancer progression. Cancer Res. 66:2683–2690. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hao XP, Willis JE, Pretlow TG, Rao JS,
MacLennan GT, Talbot IC and Pretlow TP: Loss of fragile histidine
triad expression in colorectal carcinomas and premalignant lesions.
Cancer Res. 60:18–21. 2000.PubMed/NCBI
|
|
14
|
Mori M, Mimori K, Masuda T, Yoshinaga K,
Yamashita K, Matsuyama A and Inoue H: Absence of Msh2 protein
expression is associated with alteration in the FHIT locus and Fhit
protein expression in colorectal carcinoma. Cancer Res.
61:7379–7382. 2001.PubMed/NCBI
|
|
15
|
Andachi H, Yashima K, Koda M, Kawaguchi K,
Kitamura A, Hosoda A, Kishimoto Y, Shiota G, Ito H, Makino M, et
al: Reduced Fhit expression is associated with mismatch repair
deficiency in human advanced colorectal carcinoma. Br J Cancer.
87:441–445. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sarli L, Bottarelli L, Azzoni C, Campanini
N, Di Cola G, Bader G, Iusco D, Salvemini C, Caruso G, Donadei E,
et al: Abnormal Fhit protein expression and high frequency of
microsatellite instability in sporadic colorectal cancer. Eur J
Cancer. 40:1581–1588. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Al-Temaimi RA, Jacob S, Al-Ali W, Thomas
DA and Al-Mulla F: Reduced FHIT expression is associated with
mismatch repair deficient and high CpG island methylator phenotype
colorectal cancer. J Histochem Cytochem. 61:627–638. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brown JR and DuBois RN: COX-2: A molecular
target for colorectal cancer prevention. J Clin Oncol.
23:2840–2855. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sheehan KM, O'Connell F, O'Grady A, Conroy
RM, Leader MB, Byrne MF, Murray FE and Kay EW: The relationship
between cyclooxygenase-2 expression and characteristics of
malignant transformation in human colorectal adenomas. Eur J
Gastroenterol Hepatol. 16:619–625. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sinicrope FA, Lemoine M, Xi L, Lynch PM,
Cleary KR, Shen Y and Frazier ML: Reduced expression of
cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal
cancers relative to sporadic cancers. Gastroenterology.
117:350–358. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Karnes WE Jr, Shattuck-Brandt R, Burgart
LJ, DuBois RN, Tester DJ, Cunningham JM, Kim CY, McDonnell SK,
Schaid DJ and Thibodeau SN: Reduced COX-2 protein in colorectal
cancer with defective mismatch repair. Cancer Res. 58:5473–5477.
1998.PubMed/NCBI
|
|
22
|
Ogino S, Brahmandam M, Kawasaki T, Kirkner
GJ, Loda M and Fuchs CS: Combined analysis of COX-2 and p53
expressions reveals synergistic inverse correlations with
microsatellite instability and CpG island methylator phenotype in
colorectal cancer. Neoplasia. 8:458–464. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Toyota M, Shen L, Ohe-Toyota M, Hamilton
SR, Sinicrope FA and Issa JP: Aberrant methylation of the
Cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res.
60:4044–4048. 2000.PubMed/NCBI
|
|
24
|
Japanese General Rules for Clinical and
Pathological Studies on Cancer of the Colon, Rectum and Anus.
Japanese Society for Cancer of the Colon and Rectum. 2009.
|
|
25
|
Schlemper RJ, Riddell RH, Kato Y, Borchard
F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Fléjou JF,
Geboes K, et al: The Vienna classification of gastrointestinal
epithelial neoplasia. Gut. 47:251–255. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saitoh Y, Waxman I, West AB, Popnikolov
NK, Gatalica Z, Watar J, Obara T, Kohgo Y and Pasricha PJ:
Prevalence and distinctive biologic features of flat colorectal
adenomas in a North American polulation. Gastroenterology.
120:1657–1665. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Beak MJ, Kang H, Kim SE, Park JH, Lee JS,
Paik YK and Kim H: Expression of hMLH1 is inactivated in the
gastric adenomas with enhanced microsatellite instability. Br J
Cancer. 85:1147–1152. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jass JR: Classification of colorectal
cancer based on correlation of clinical, morphological and
molecular features. Histopathology. 50:113–130. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Inoue A, Okamoto K, Fujino Y, Nakagawa T,
Muguruma N, Sannomiya K, Mitsui Y, Takaoka T, Kitamura S, Miyamoto
H, et al: B-RAF mutation and accumulated gene methylation in
aberrant crypt foci (ACF), sessile serrated adenoma/polyp (SSA/P)
and cancer in SSA/P. Br J Cancer. 112:403–412. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vaiphei K, Rangan A and Singh R: Aberrant
crypt focus and fragile histidine triad protein in sporadic
colorectal carcinoma. World J Gastrointest Oncol. 4:250–258. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dong SM, Lee EJ, Jeon ES, Park CK and Kim
KM: Progressive methylation during the serrated neoplasia pathway
of the colorectum. Mod Pathol. 18:170–178. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kawasaki T, Nosho K, Ohnishi M, Suemoto Y,
Glickman JN, Chan AT, Kirkner GJ, Mino-Kenudson M, Fuchs CS and
Ogino S: Cyclooxygenase-2 overexpression is common in serrated and
non-serrated colorectal adenoma, but uncommon in hyperplastic polyp
and sessile serrated polyp/adenoma. BMC Cancer. 8:332008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Takeuchi M, Kobayashi M, Ajioka Y, Honma
T, Suzuki Y, Azumaya M, Narisawa R, Hayashi S and Asakura H:
Comparison of cyclo-oxygenase 2 expression in colorectal serrated
adenomas to expression in tubular adenomas and hyperplastic polyps.
Int J Colorectal Dis. 17:144–149. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Arao J, Sano Y, Fujii T, Kato S, Fu KI,
Yoshino T, Ochiai A, Fujimori T and Yoshida S: Cyclooxygenase-2 is
overexpressed in serrated adenoma of the colorectum. Dis Colon
Rectum. 44:1319–1323. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Maekawa M, Sugano K, Sano H, Miyazaki S,
Ushiama M, Fujita S, Gotoda T, Yokota T, Ohkura H, Kakizoe T and
Sekiya T: Increased expression of cyclooxygenase-2 to −1 in human
colorectal cancers and adenomas, but not in hyperplastic polyps.
Jpn J Clin Oncol. 28:421–426. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Castells A, Payá A, Alenda C,
Rodríguez-Moranta F, Agrelo R, Andreu M, Piñol V, Castellví-Bel S,
Jover R, Llor X, et al: Cyclooxygenase 2 expression in colorectal
cancer with DNA mismatch repair deficiency. Clin Cancer Res.
12:1686–1692. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wasa R, Matsukuma S, Abe H, Kuwabara N,
Suda K, Arakawwa A and Kitamura S: Histopathological studies of
superficial-type early colorectal carcinoma. Cancer. 77:44–50.
1996. View Article : Google Scholar : PubMed/NCBI
|
